pharma news

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

News

Novartis shares fall as Entresto sales weaken

Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.

News

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

News

Intellia’s president and chief executive John Leonard

Intellia files CRISPR drug after historic phase 3 readout

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

News

Lilly's M&A team strikes again with $2.3bn Ajax takeover

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.

News

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.

GSK eyes October FDA verdict on chronic hep B drug

Novartis shares fall as Entresto sales weaken

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Intellia files CRISPR drug after historic phase 3 readout

Lilly's M&A team strikes again with $2.3bn Ajax takeover

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks